First in Human Study of QLS5316 in Solid Tumors

Summary

This is a first-in-human (FIH) Phase I, multi-center, open-label, study of QLS5316, in patients with advanced solid tumors. The study aim to evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of QLS5316 as monotherapy.

Timeline

Start

2026-01

Primary completion

2027-12

Completion

2027-12

Drugs

Indications